GlobeNewswire Inc | Jul 30, 2020 08:00AM EDT

July 30, 2020

Conference call and webcast to be held at 10:00 a.m. ET

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at10:00 a.m. ET onAugust 6, 2020, to provide a business update and review the companys financial results for the second quarter ended June 30, 2020.

To access the live conference call by phone, please dial 877-407-0792(domestic) or 201-689-8263 (international), and provide the access code 13706144. A live audio webcast will be accessible from the Media & Investors page of Albireos website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireos website for 3 months following the event.

About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireos clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.

Albireo was spun out fromAstraZenecain 2008.Albireo Pharmais located inBoston, Mass., and its key operating subsidiary is located inGothenburg, Sweden. TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year. For more information on Albireo, please visitwww.albireopharma.com.

Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462,clacagnina@6degreespr.com